Core Insights - The stock price of Sinocare Inc. (02591) increased by 5.37%, currently trading at HKD 32.60, with a transaction volume of HKD 33.25 million [1][4] - The first domestically developed ultra-long-acting human GLP-1 receptor agonist, Icosapent Ethyl (brand name: Yinuo Qing®), has been officially included in the 2025 National Medical Insurance Drug List, effective from January 1, 2026, aimed at controlling blood sugar in adult patients with type 2 diabetes [1][4] - This inclusion marks a significant step towards the accessibility of innovative diabetes treatments in China, aligning with the "Healthy China 2030" initiative [1][4] Industry Developments - The National Guidelines for Diabetes Prevention and Control (2025) have classified Icosapent Ethyl as a GLP-1 receptor agonist injectable, providing direct policy and regulatory support for its use in primary healthcare institutions [1][4] - The guidelines emphasize the importance of GLP-1 receptor agonists as a treatment option for adult type 2 diabetes patients with comorbidities such as atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and those requiring weight management [1][4]
银诺医药-B午前涨超5% 依苏帕格鲁肽ɑ获国家基层糖尿病防治指南推荐